SCL Science has signed a memorandum of understanding (MOU) with Hue Central Hospital, a national hospital in Vietnam, and joined forces with a local medical device distributor. The company is pushing ahead with on-site usage demonstrations and regulatory approval for its flagship surgical hemostatic agent “InnoSeal Plus DL” as it moves to enter the Vietnamese market.

SCL Science announced on the 20th that it had signed an MOU with Hue Central Hospital for joint research, medical technology exchange, and the introduction of medical devices. It also concluded a local distribution partnership agreement for InnoSeal Plus DL with Keynoty System, a company specializing in supporting entry into the Vietnamese medical device market.

Founded in 1894, Hue Central Hospital is a national general hospital designated as “Special Class,” the highest grade, by the Vietnamese Ministry of Health. Operating more than 5,500 beds, it is a major medical institution in central Vietnam that performs high‑complexity procedures such as cardiac surgery and organ transplantation.

Under this agreement, Keynoty System will promote product usage demonstrations at Hue Central Hospital and take charge of local regulatory approval procedures. After approval is obtained, it will be responsible for product distribution and expansion of sales.

An SCL Science official said, “If the regulatory process is carried out through a local partner, there is a high possibility of obtaining approval within six months to one year,” adding, “Medical devices that have received item approval from the Ministry of Food and Drug Safety in Korea are understood to be eligible for a fast‑track registration procedure in Vietnam.”

Hue Central Hospital is considering starting product demonstrations focusing on liver resection surgery. The SCL Science official said, “The field in which the hemostatic performance of InnoSeal Plus DL has been verified through the largest number of cases is liver resection surgery,” adding, “We are considering hemostasis success rate within three minutes, rebleeding rate, and device‑related adverse events as key evaluation metrics.” The scale of the demonstrations has not yet been determined.

InnoSeal Plus DL is a bioabsorbable internal hemostatic product applied to bleeding sites during surgery. Unlike conventional fibrin patch‑type products that use coagulation proteins, it is characterized by the use of a chitosan–catechol material. In Korea, it received manufacturing approval as a medical device last year, and in May this year it obtained a variation approval expanding its use from conventional liver resection to a broader range of intra‑abdominal soft tissue surgeries.

The SCL Science official said, “Conventional fibrin patch or gel‑type hemostatic agents inevitably incur higher production costs because they contain coagulation proteins, whereas InnoSeal Plus DL uses a material that can deliver hemostatic performance without coagulation proteins,” adding, “The ability to lower production costs and supply prices is its price competitiveness.”

The company will also promote joint research with Hue Central Hospital. It plans to secure clinical use cases in a variety of surgical procedures and laparoscopic interventions beyond liver resection surgery to broaden the product’s range of applications.

In addition to Vietnam, the company is also seeking to enter the Mongolian and Russian markets. The SCL Science official said, “In Mongolia, we can leverage SCL Group’s local network, and in Russia, following the supply contract signed last year, we are preparing for regulatory approval,” adding, “There is a high possibility that these two markets will become the first stepping stones for global expansion.”

Popular News